Purpose We previously observed that poor DNA repair phenotype is associated with increased breast cancer (BC) risk within families. Here, we examined whether genetic variation in double-strand break repair (DSBR) genes is associated with BC risk and if genotypes are related to phenotype in unaffected women. Methods Using data from the New York site of the Breast Cancer Family Registry, we investigated 25 single-nucleotide polymorphism (SNPs) involved in DSBR using biospecimens from 337 BC cases and 410 unaffected sister controls. Results Genotypes in XRCC4 were associated with BC risk, with ORs of 1.67 (95 % CI 1.01-2.76) for the combined GA/AA of rs1805377 and 1.69 (95 % CI 1.03-2.77) for rs1056503 TG/GG; these associations were no longer statistically significant in multivariable conditional logistic regression models. When examining the association of SNPs with phenotype, we found that genotypes of XRCC5 rs3834 and rs1051685, which were highly correlated with each other, were associated with end-joining (EJ) capacity; women with the XRCC5 rs3834 GA genotype had better DNA repair as measured by higher levels of EJ capacity (37.8 ± 14.1 % for GA vs. 27.9 ± 11.8 % for GG carriers p = 0.0006). Women with the AA genotype of BRCA1 rs799917 also had higher EJ capacity (35.1 ± 9.2 %) than those with GG (26.4 ± 10.1 %, p = 0.02). Conclusions Overall, we found that selected DSBR genotypes were associated with phenotype, although they were not associated with BC risk itself, suggesting that phenotypic measures are influenced by endogenous and exogenous factors across the life course and may be better markers than genotypic measures for ascertaining BC risk. 
Introduction
DNA double-stranded breaks (DSB), induced directly from exposure to ionizing radiation or the result of endogenous or exogenous exposures, play an important role in tumorigenesis [1, 2] . In humans, two main repair pathways are responsible for repairing DSB: (1) non-homologous endjoining (NHEJ), which involves direct DNA end-joining and requires no sequence homology [3] and (2) homologous recombinational repair (HRR) [4] , which relies on extensive nucleotide sequence complementarity between the intact and the damaged DNA strands as the basis for strand exchange and repair. DSB repair (DSBR) mechanisms are important to breast cancer (BC) as evidenced by the key major BC susceptibility genes, BRCA1 and BRCA2 [5] , as well as supported by increased chromatid damage in x-irradiation-treated blood lymphocytes of BC patients and their first-degree relatives [6] . In addition, a study of genome-wide loss of heterozygosity suggested that BC pathogenesis is driven by DSB-initiated chromosome instability [7] . Thus, it is plausible that polymorphisms in DSBR genes may alter normal protein activity and/or binding and thus affect DSBR efficiency, leading to genomic instability, and increased BC risk.
Although some studies have suggested that SNPs in DSBR genes are related to modest increases in BC risk [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , much of the evidence has been mixed and primarily examined in women at average risk and largely without integration of DNA repair phenotype data. Within families at higher risk of BC, we previously reported an association of impaired in DSBR capacity and increased BC risk [21] . Our results suggested that suboptimal DSBR capacity was associated with 2-4 times the risk of BC compared with women with optimal DSBR capacity [21] . Using data from the New York site of the Breast Cancer Family Registry (BCFR), we investigated 25 SNPs in 11 genes involved in DSBR using biospecimens from 337 BC cases and 410 sister controls unaffected by BC from 304 families. We also investigated the role of these SNPs in DNA endjoining (EJ) capacity in a subset 91 unaffected individuals for which EJ capacity data were available using blunt and sticky end substrates [21] .
Materials and methods

Study participants
We conducted our study using data from families participating in the New York site of the BCFR, a six-site international registry (California, New York, Philadelphia and Utah in the USA, Ontario in Canada, and Melbourne and Sydney in Australia) [22] . The New York site recruited high-risk breast and/or ovarian cancer families from clinical and community settings within the metropolitan New York area. We recruited families if they met one of the following criteria: (1) have a female relative with breast or ovarian cancer diagnosed before age 45 years, (2) have a female relative with both breast and ovarian cancer regardless of age at diagnosis, (3) have two or more relatives with breast or ovarian cancer diagnosed after age 45 year, (4) be a male with breast cancer diagnosed at any age, or (5) have a family member with a known BRCA mutation. Family members completed an epidemiologic questionnaire to provide information on demographics, family history of cancer, ethnicity, smoking, alcohol consumption, reproductive history, hormone use, weight, height, and physical activity, and a self-administered food frequency questionnaire to provide information on diet.
We collected blood from participants at the time of recruitment to permit the isolation of plasma and white blood cells (WBC) fractions. For this study, we used a family-based study design with sister sets discordant for BC [21, [23] [24] [25] [26] [27] . Specifically, we used information from a total of 337 affected sisters with BC and 410 unaffected sisters with blood DNA available for genotyping. Among them, DNA EJ capacity in lymphoblastoid cell lines was available for a total of 91 unaffected sisters [21] . The study was approved by Columbia University's Institutional Review Board.
SNP selection and genotyping
We selected 25 SNPs from 11 DSBR genes [ATM (rs1801516 and rs664677), BRCA1 (rs1799966 and rs799917), BRCA2 (rs766173 and rs144848), NBS1 (rs1805794 and rs1805787), XRCC3 (rs1799794), RAD51 (rs1801321), RAD52 (rs11226), LIG4 (rs1805388), XRCC4 (rs1805377, rs2075685, rs1056503, rs1478485, rs13180316, and rs963248), XRCC5 (rs2440, rs1051677, rs3835, rs3834, rs828699, and rs1051685), and XRCC6 (rs132793)]. Our selection of DSBR SNPs was based on the following criteria: (a) associated with cancer risk at any site in epidemiologic studies, (b) a minor allele frequency of at least 5 %, or (c) coded for missense changes. Although the biological effect of most SNPs selected for study is not known, we expected that these criteria would maximize the likelihood of choosing SNPs with functional significance and with a possible association with BC.
We extracted genomic DNA from WBC by salting out procedures and genotyped in a combination of BioTrove OpenArray TM system (Applied Biosystems, Foster City, CA) with TaqMan assays and 384 well TaqMan assays. For the BioTrove platform, we used 200 ng of DNA (2 ul) in an array with 3,072 through-holes arranged in a pattern of 96 sub-arrays. The PCR mixtures included 19 (144 ul) TaqMan Universal PCR Master Mix (Applied Biosystems), 1 % (14.4 ul) Pluronic F38 (BioTrove, Woburn, MA), 0.5 % (9.6 ul) glycerol (Sigma-Aldrich, St. Louis, MO), 0.05 mg/ml (1.5 ul) BSA (Sigma-Aldrich) and 5.0 ul PCR-grade water (Sigma-Aldrich). The OpenArray TM AutoLoader enables loading of the mixed solution (DNA and PCR mixture) onto an OpenArray TM plate from a 384-well plate. The PCR thermal cycling protocol consisted of 92°C for 10 min followed by 50 cycles of 92°C for 15 s, 55°C for 1 min and 72°C for 1 min (imaging step). Following amplification, amplicon dissociation was measured by cooling the PCR array to 65°C then slowly heating to 92°C for 1°C per min, with images collected every 0.25°C.
We used the ''Image'' program to obtain the three genotyping clusters in the scatter plot. Samples that failed to amplify on the array were genotyping using the TaqMan assays in 384 well assays. Samples that failed on both platforms were indicated as missing. We verified genotype reproducibility by randomly duplicating 5 percent of DNA samples (100 % consistency was found).
DNA end-joining capacity assay
We evaluated DNA repair capacity in the DSBR pathway by fluorescence measurement of the end-joined products using two different substrates with blunt (HincII cut) or sticky (EcoRI cut) ends as described previously [21] . Each EJ reaction included a negative control, also run in duplicate of one of that day's test samples after heat denaturing. T4 ligase was run as a positive control in each experiment.
As an additional quality control, a large batch of nuclear proteins were isolated from a randomly selected cell line and assayed in each EJ reaction and gel run. The products of controls were run in every gel together with the actual samples. The percentage of EJ was expressed as (intensity of EJ products/total substrate) 9100 %. We performed all assays blinded to the subject's case-control status.
Statistical methods
We tested Hardy-Weinberg equilibrium (HWE) by the v2 test in unaffected sisters. Although six (rs1805388, rs1805377, rs1056503, rs2440, rs3834, and rs1051685) did not pass the HWE test at p = 0.05, we did not exclude these SNPs from the data analysis. We used ANOVA test to compare differences in EJ capacity across the various genotypes among unaffected sisters.
We used conditional logistic regression models to estimate within-family odd ratios (ORs) and 95 % confidence intervals (CIs) for the main effect of genotype on BC risk. To determine the independent effects of SNPs on BC risk, we then estimated the ORs for each genotype adjusting for all SNPs simultaneously in multivariable conditional logistic regression models. In these models adjusting for age, we included all the SNPs except XRCC4 (rs1805377) and XRCC5 (rs1051685). These SNPs were excluded in the full model because of their strong correlation with other SNPs at the same locus. To determine the collinearity between SNPs, we used the Spearman correlation test to examine the correlation between SNPs. XRCC4 rs1056503 and rs1805377 and XRCC5 rs3834 and rs1051685 were significantly correlated with each other with spearman correlation coefficients of 0.994 (p \ 0.0001) and 0.989 (p \ 0.0001), respectively. In Model 2, we only retained SNPs significant at the 0.2 level in the full model. In Model 3, we only retained SNPs significant at the 0.2 level in Model 2. All models were adjusted for age.
In addition to the conditional logistic regression models which examined within-family differences in genotype and BC risk, we also assessed population average effects of the genotype on BC risk through the use of generalized estimating equations (GEE) [28] . We were able to include women who did not have sibling controls in the GEE analyses. All analyses were performed with SAS software 9.2 (SAS Institute, Cary, NC).
Results
The distributions of demographic characteristics between cases and their unaffected sister controls were reported in the previously studies [23, 25] . In brief, the distributions of race and age at blood draw were similar between cases and their unaffected sister controls. BRCA mutation frequencies were higher in cases than in controls (8.2 vs. 3.7 % for BRCA1 and 4.3 vs. 2.6 % for BRCA2). There were no differences in age at menarche and hormone replacement therapy use between cases and their sister controls.
Breast cancer risk and genetic variation in DSBR genes
The overall effects of the single SNPs in genes in the NHEJ pathway on BC risk are given in Table 1 . The combined OR for GA/AA genotypes of XRCC4 rs1805377 was 1.67 (95 % CI 1.01-2.76). We also observed a statistically significant effect of the combined TG/GG XRCC4 rs1056503 genotypes with BC with an OR of 1.69 (95 % CI 1.03-2.77) when compared with subjects with the TT genotype. Variant genotypes in XRCC5 rs1051677 were inversely associated with BC. The OR for the combined TC/CC genotypes was of 0.61 (95 % CI 0.33-1.22). Eleven SNPs in genes involved in HRR were analyzed, and results are reported in Table 2 . We found modest associations of BC risk with SNPs in ATM rs1801516, RAD52 rs11226, and BRCA2 rs766173, but these associations were not statistically significant.
We performed an analysis adjusting simultaneously for all SNPs except XRCC4 rs1805377 and XRCC5 rs1051685 because of their strong correlation with other SNPs (see ''Statistical methods''). Table 3 shows the adjusted conditional logistic regression models as well as GEE models. Overall, there were elevated associations for RAD52 rs11226 GA/AA genotypes (OR = 1.58, 95 % CI 0.93-2.70), XRCC4 rs1056503 GT/GG genotypes (OR = 1.52, 95 % CI 0.91-2.55) and XRCC5 rs3834 GA/ AA genotypes (OR = 1.59, 95 % CI 0.88-2.90); however, these associations were not statistically significant. Similar results were obtained using GEE models. Only the RAD52 GA/AA genotype was of borderline statistical significance in the final model with an OR of 1.26 (95 % CI 0.97-1.64).
End-joining capacity and SNPs in DSBR genes
Associations of EJ capacity with SNPs in the NHEJ pathway are given in Table 4 among sisters unaffected by BC. XRCC5 rs3834 and rs1051685 were significantly associated with EJ capacity. Carriers of the XRCC5 rs3834 homozygous GG genotype have lower EJ capacity than variant carriers. Heterozygous GA and homozygous AA subjects have EJ levels of 37.8 ± 14.1 % and 33.0 ± 10.6 %, respectively, versus 27.9 ± 11.8 % for the GG subjects (p = 0.0006) when using the blunt end substrate. The differences between mean values of repair capacity were similar for the sticky end substrate. We also found that carriers of the XRCC5 rs1051685 AG heterozygous genotype have EJ capacity levels of 38.0 ± 14.4 %, while the other genotypes have lower values (27.8 ± 11.8 % for AA and 32.5 ± 12.2 % for GG, p = 0.006) when assaying the blunt end substrate. These results were highly consistent with the correlation between genotypes of XRCC5 rs3834 and rs1051685. The mean EJ values for the sticky and blunt end substrates were also similar. Table 5 shows the EJ capacity by HRR SNP genotypes among sisters unaffected by BC. While most HRR genotypes tested showed no significant effect on EJ capacity, we found a statistically significant effect for BRCA1 rs799917 genotype with the sticky end substrate (Table 5) . EJ capacity was significantly higher for carriers of the AA genotype (35.1 ± 9.2 %) than for carriers of the GA (29.9 ± 10.9 %) and GG (26.4 ± 10.1 %) genotypes. This increase in EJ capacity corresponded with a statistically significant dose-response trend (p = 0.02). While a similar increase was observed with the blunt end substrate, the difference was not statistically significant.
Discussion
We screened 25 SNPs in 11 DSBR genes and found that SNPs in XRCC5, XRCC4 and BRCA1 were associated with BC and/or had an effect in EJ capacity. However, the associations with BC risk were no longer significant in multivariable conditional logistic regression models. A role for the DSBR pathway in breast tumorigenesis has been suggested by both genetic association [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and phenotypic studies [21, 29, 30] . However, there are limited data on genotype and DSBR phenotype within higher risk women. We found significantly associations with BC for XRCC5 rs1051677, XRCC4 rs1056503, and XRCC4 rs1805377 variants; however these associations were no longer present in the adjusted logistic regression and GEE models. We found six SNPs did not pass the HWE test in unaffected sisters. The SNPs that did not pass in XRCC4 and XRCC5 were highly correlated. The strong correlation may be related to differences in genotype inheritance in higher risk families rather than genotyping error. We found statistically significant differences in EJ capacity for carriers of different variants of XRCC5 rs3834 and its correlated SNP, rs1051685, and one BRCA1 variant, rs799917. In this study, only variants of XRCC5 rs3834 were associated with altered EJ capacity, and there was a borderline association with increased BC risk. XRCC5 encodes Ku80, one of the two partners of the DSB-binding complex that initiates NHEJ [31] . This complex recruits additional proteins to the DSB for further processing and functions to prevent degradation of the DSB ends to conserve genetic information and to allow for efficient repair [32] . In support of this enzyme's requirement for NHEJ, in vitro studies with XRCC5 mutant cell lines have shown that the frequency of DNA end-joining decreases 1000-fold in the absence of this protein [33] . In this study, we found that XRCC5 rs1051677 CC genotype was associated with decreased BC risk. In addition, we found there is a high correlation between genotypes in XRCC5 rs3834 and rs1051685, and both heterozygous carriers of XRCC5 rs3834 and rs1051685 individuals had higher EJ capacity when compared with carriers of the homozygous variant and wild type alleles. This unexpected association between cancer susceptibility and increased DBSR capacity suggests that we should be cautious when interpreting results obtained from phenotypic biomarker studies. The NHEJ process is error-prone as it does not use an undamaged template for the repair of a DSB [34] . Increased end-joining might indicate not a more efficient repair but a less accurate resealing of breaks, and possibly increased degradation and DNA sequence loss, a phenotype that could lead to increased cancer susceptibility. ORs in full model were adjusted for age at interview for controls or breast cancer diagnosis for cases, and SNPs (ATM rs1801516 and rs664677, BRCA1 rs1799966 and rs799917, BRCA2 rs766173 and rs144848, NBS1 rs1805794 and rs1805787, RAD51 rs1801321, XRCC3 rs1799794, LIG4 rs1805388, XRCC4 rs963248, rs1478485, rs2075685, and rs13180316, XRCC5 rs2440, rs3835, and rs828699 and XRCC6 rs132793) The BRCA1 protein plays an important role during homologous recombination [35] . Additional roles have also been described for BRCA1 during NHEJ and as a regulator of the expression of other DNA repair genes. Cell-free extracts from BRCA1-null fibroblasts have deficient NHEJ activity, and an in vivo host cell end-joining assay has shown that human cells heterozygous for BRCA1 mutations exhibit impaired fidelity of DSB end-joining [36, 37] . These data suggest that BRCA1 is necessary for faithful rejoining of broken DNA ends. Whole-cell extracts from BRCA1-deficient BC cell lines compared with BRCA1-proficient ones had decreased EJ capacity [10] . Although the precise role of BRCA1 in NHEJ remains unclear, previous work has suggested that it is likely to participate in NHEJ by virtue of its interaction with the Rad50/Mre11/ Nbs1 complex [38] . We investigated two SNPs in BRCA1 and observed that for one of them, BRCA1 rs799917, the variant AA genotype was associated with statistically significant higher EJ compared with the GG wild type genotype. This variant was also related to a non-significant decrease in BC, which might indicate a direct genotypephenotype association. The BRCA1 rs799917 SNP encodes a proline to leucine substitution at codon 871 in a highly conserved region of the protein [39] . While no functional analysis has been performed to date, this non-conservative amino acid substitution can potentially lead to altered protein function. To predict amino acid changes that might affect protein function, we performed bioinformatics analysis using SIFT (www.blocks.fhcrc.org/sift/SIFT.html) for BRCA1 rs799917. SIFT analysis indicates that this SNP results in an amino acid change L871P, which predicted to affect protein function with a score of 0.03. Our finding of an association of a variant in BRCA1, a BC susceptibility gene, with NHEJ activity, not only suggests a role for BRCA1 in NHEJ, but also provides support for the importance of the NHEJ pathway to BC development. Several studies have investigated XRCC4 genetic variation and BC risk. XRCC4 forms a complex with Ligase IV which functions during NHEJ to reseal the break [40] . A study conducted in Taiwan among Asian women found that carrying an increasing number of variant alleles in XRCC4 was associated with higher disease risk [8] . Another study found associations of XRCC4 haplotypes with age at diagnosis of BC and risk in non-BRCA1/2 heritable individuals [16] . In the current study, we examined six SNPs in XRCC4. For two of these SNPs, XRCC4 rs1056503 and rs1805377, the distributions of their genotypes were linked and we performed our analysis excluding one of them, XRCC4 rs1805377. We found XRCC4 rs1056503 to be associated with increased BC, but the association did not remain after adjusting for other SNPs. One previous population-based study in the USA and Poland found no significant effect of XRCC4 rs1805377 on BC risk [9] . Double-strand breaks are converted to homologous joint molecules by invasion of a homologous duplex by singlestrand DNA. Normal formation of homologous joint molecules and recombination products during meiosis requires several mitotic repair genes including RAD52 [41] . In a single SNP model, the RAD52 rs11226 GA/AA genotypes were associated with BC with an OR of 1.53 (95 % CI 0.90-2.59). In the model section process adjusted for multiple variables, the effect of genotypes of RAD52 rs11226 remains of borderline significance in both conditional regression and GEE models, suggesting that variation in RAD52 might be important for familial BC risk.
Family history is well-recognized as a strong risk factor for female BC [42] . Only about 4-5 % of breast cancers are caused by known mutations in cancer susceptibility genes, such as BRCA1 and BRCA2 [43] , suggesting that additional low-penetrance genetic variants might contribute to BC, particularly among higher risk women. Our study has the advantage of having higher risk women in the study to examine whether DNA repair phenotype and genotype are important predictors within these families. Within-family comparisons can reduce confounding from population admixture for genetic association studies as well as familylevel factors, confounding factors that may affect phenotypic differences [44] . In addition to the within-family analyses, which are likely underpowered, we were able to estimate our associations with genotype using generalized estimating equations. The overall inferences from these two approaches were very similar suggesting that there was minimal unmeasured fixed family-level confounding of these associations. Our SNPs selection criteria were strong and based on important requirements. Our inability to detect differences in DSB repair capacity by and BC risk and genotype was not surprising because we only included about 25 % of the core genes in the DSBR pathways [45] and some SNPs such as RAD51L1 rs999737 consistently related to BC in several genome-wide association studies were not examined in our study [46] [47] [48] .
Studies of phenotypic biomarkers are considered to capture more of the pathway effects than studies of genetic variation alone, as phenotype measures help account for multiple enzymatic activities and protein interactions.
However, these studies are difficult to perform, and our inability of accurately mimic in vivo conditions limits the interpretability of the data. Our results of genotype-phenotype association analysis support the importance of XRCC5 and BRCA1 in familial BC risk. These findings further highlight the importance of DNA repair phenotype in explaining breast cancer risk and suggest that genetic variation may explain only a small percent of DSB repair capacity, and there are other factors that may contribute to individual differences in EJ capacity. Methylation in the promoter regions of gene resulting in silencing gene expression is one of the common epigenetic alterations observed in BC (reviewed in [49] ). Methylation in the promoter regions of DNA repair genes such as BRCA1 was associated with BC risk [50] . Differences in the methylation of DNA repair genes might explain some of the variation in the DNA repair capacity between sisters, and future studies are needed to examine both genetic and epigenetic effects on phenotype.
